Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...

BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...

CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight. Reformation for the ...

Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026. In an interview with Bloomberg TV ...

Deloitte notes that many companies are trying to capture a share of the $200 billion GLP-1 drug market. Beyond obesity, potential indications for these drugs include sleep apnea, addiction ...